Avoro Capital Advisors is a global firm focused on funding & investments in biotechnology, life sciences, and specialty therapeutics. Contact us today!
Employees: 11-50
Portfolio 67
| Date | Name | Website | Total Raised | Location |
| 20.05.2025 | Krystal Bi... | krystalbio.com | - | United Sta... |
| 20.05.2025 | Merus N.V. | merus.nl | $157.12M | Netherland... |
| 20.05.2025 | Scorpion T... | scorpiontx.com | $420M | United Sta... |
| 20.05.2025 | CRISPR The... | crisprtx.com | $127M | United Sta... |
| 20.05.2025 | Ottimo Pha... | ottimopharma.com | $140M | - |
| 20.05.2025 | Rocket Pha... | rocketpharma.com | - | United Sta... |
| 20.05.2025 | Zealand Ph... | zealandpharma.com | $200M | Denmark |
| 20.05.2025 | Tourmaline... | tourmalinebio.com | $75M | - |
| 20.05.2025 | Viking The... | vikingtherapeutics.com | $15M | United Sta... |
| 20.05.2025 | ViceBio | vicebio.com | $100M | - |
Show more
Persons 12
| Date | First Name | Last Name | Title | Location | |||
| - | Molly | Reichhard | Receptioni... | - | - | - | |
| - | Lauren | Godlasky | Head of In... | - | - | - | |
| - | Susana | Wilson Haw... | PhD | Asso... | - | - | - | |
| - | Karan | Naik | MD | Assoc... | - | - | - | |
| - | Billy | Smith | Associate | - | - | - | |
| - | David | Xiang | MD MPH | A... | - | - | - | |
| - | Behzad | Aghazadeh | PhD | Mana... | - | - | - | |
| - | Jenna | McElhinney | Manager | ... | - | - | - | |
| - | Neil | Cammarosan... | CPA | Chie... | - | - | - | |
| - | Jenna | Glatzer | PhD | Asso... | - | - | - |
Show more
Mentions in press and media 7
| Date | Title | Description |
| 28.10.2025 | Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies | Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB... |
| 27.10.2025 | Hemab Therapeutics: $157 Million Series C Secured For Advancing Treatments For Underserved Bleeding Disorders | Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious bleeding and thrombotic disorders, announced that it has completed a $157 million Series C financing. The oversubscribed fundi... |
| 20.12.2024 | Ottimo Pharma: A New Dawn in Cancer Treatment with $140 Million Boost | In the world of biotechnology, every dollar counts. Ottimo Pharma, a New York City-based biotech firm, has just raised over $140 million in a Series A funding round. This infusion of capital is not just a financial milestone; it’s a beacon ... |
| 20.12.2024 | Ottimo Pharma: Over $140 Million (Series A) Raised To Advance Bifunctional Medicines | Ottimo Pharma – a private biotech company pioneering bifunctional medicines to extend the lives of people with cancer – announced the completion of a Series A financing round of over $140 million. The funding round was led by OrbiMed, Avoro... |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies – – Lead program targets Parkinson’s disease and all forms of Gaucher disease – C... |
| 19.03.2021 | Monte Rosa closes $95 million series C round | |
| 19.03.2021 | Monte Rosa closes $95 million series C round | Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine based in Basel and is active in both Boston and Basel. With the core focus on discovering and developing molecular glues to degrade disease-causing ... |